Literature DB >> 29893652

Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing.

Mark S Freedman1, Daniel Selchen2, Alexandre Prat3, Paul S Giacomini4.   

Abstract

Recent therapeutic advances in the management of multiple sclerosis (MS) have raised questions about the selection of appropriate patient candidates for various treatments and, if the plan is to move from one treatment to another, the appropriate sequencing of these therapies. The selected approach should provide optimal disease management without limiting future therapeutic options based on safety concerns, and recognize potential future treatments and the possibility of combination therapies. Additional challenges include incorporation of patient needs and preferences into the overall therapeutic approach, in order to ensure optimal outcomes in the short and long term. The objective of this manuscript is to provide an overview of what is currently known regarding the impact of various therapies for MS on future therapeutic choices (sequencing). In this context, we reviewed the available evidence in support of various treatments and, based on the presence of disease activity, suggested a scheme for switching or escalating therapy with the main focus on sequencing of therapeutic approaches.

Entities:  

Keywords:  Long-term outcome; Multiple sclerosis; Relapsing remitting

Mesh:

Year:  2018        PMID: 29893652     DOI: 10.1017/cjn.2018.17

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

1.  Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.

Authors:  Damiano Paolicelli; Giuseppe Lucisano; Alessia Manni; Carlo Avolio; Simona Bonavita; Vincenzo Brescia Morra; Marco Capobianco; Eleonora Cocco; Antonella Conte; Giovanna De Luca; Francesca De Robertis; Claudio Gasperini; Maurizia Gatto; Paola Gazzola; Giacomo Lus; Antonio Iaffaldano; Pietro Iaffaldano; Davide Maimone; Giulia Mallucci; Giorgia T Maniscalco; Girolama A Marfia; Francesco Patti; Ilaria Pesci; Carlo Pozzilli; Marco Rovaris; Giuseppe Salemi; Marco Salvetti; Daniele Spitaleri; Rocco Totaro; Mauro Zaffaroni; Giancarlo Comi; Maria Pia Amato; Maria Trojano
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

2.  Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.

Authors:  Robert J Fox; Rina Mehta; Timothy Pham; Julie Park; Kathleen Wilson; Machaon Bonafede
Journal:  BMC Neurol       Date:  2022-06-07       Impact factor: 2.903

3.  Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists.

Authors:  Gustavo Saposnik; Xavier Montalban; Daniel Selchen; Maria A Terzaghi; Fabien Bakdache; Alonso Montoya; Manuel Fruns; Fernando Caceres; Jiwon Oh
Journal:  Front Neurol       Date:  2018-09-24       Impact factor: 4.003

4.  Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?

Authors:  Yan Shi; Minna Guo; Wenjing Yang; Shijiang Liu; Bin Zhu; Ling Yang; Chun Yang; Cunming Liu
Journal:  Expert Rev Vaccines       Date:  2021-04-12       Impact factor: 5.217

5.  Effect of an Educational Intervention on Therapeutic Inertia in Neurologists With Expertise in Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Gustavo Saposnik; Marcus Grueschow; Jiwon Oh; Maria A Terzaghi; Pawel Kostyrko; Shruthi Vaidyanathan; Rosane Nisenbaum; Christian C Ruff; Philippe N Tobler
Journal:  JAMA Netw Open       Date:  2020-12-01

Review 6.  Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process.

Authors:  Olympia Damianidou; Paschalis Theotokis; Nikolaos Grigoriadis; Steven Petratos
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

Review 7.  Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.

Authors:  Gavin Giovannoni; Joela Mathews
Journal:  Neurol Ther       Date:  2022-03-23

8.  A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.

Authors:  Pierre Duquette; Michael Yeung; Soukaïna Mouallif; Hamid Reza Nakhaipour; Paola Haddad; Robyn Schecter
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.